資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSIHS_EWB_GF

Genome Editing / Genome Engineering Market by Application, Technology & End User - Global Forecast to 2019

  • LinkedIn
  • facebook
  • Twitter
出 版 商:MarketsandMarkets
出版日期:2015/05/07
頁  數:155頁
文件格式:PDF
價  格:
USD 4,650 (Single-User License)
USD 5,650 (Multi-User License)
USD 9,000 (Global-User License)
線上訂購或諮詢
In this report, the genome editing market is segmented on the basis of applications, technologies, end users, and regions. The application segments included in this report are cell line engineering, animal genetic engineering, plant genetic engineering, and other applications. The genome editing market, by technology, is categorized into CRISPR, TALEN, ZNF, antisense technology, and other technologies. The end-user segment includes biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations (CROs).

The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). Asia is further divided into the regional segments of China, India, Japan, and Rest of Asia; and North America is divided into Canada and the U.S.

Growth in the genome editing market is mainly driven by the increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increased funding for genomics research, technological advancements, increasing demand for synthetic genes, and global rise in production of genetically modified crops. The high growth potential in emerging markets provides new growth opportunities to players in the genome editing market.

A combination of the bottom-up and top-down approach was used to calculate the market sizes and growth rates of the global genome editing market and its subsegments. Secondary information was used to identify the overall revenue, geographic reach, and product portfolios of the market players. Estimates of the genome editing market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on the key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each segment and identifies the segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the genome editing market. The company profiles include the financial performances, product portfolios, and developments of each company; whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as mergers and acquisitions; agreements, collaborations, and partnerships; expansions; and new product launches.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions.

The report provides insights on the following:
‧ Product Development/Innovation: Product portfolios of the top players in the genome editing market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the genome editing market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the genome editing market
‧ Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various genome editing segments across geographies
‧ Market Diversification: Exhaustive information about new products, recent developments, and investments in the genome editing market
TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.3 MARKET SHARE ESTIMATION 25
2.3.1 KEY DATA FROM SECONDARY SOURCES 25
2.3.2 KEY DATA FROM PRIMARY SOURCES 25
2.3.3 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL GENOME EDITING MARKET 31
4.2 LIFE CYCLE ANALYSIS, BY REGION 32
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 35
5.2 MARKET SEGMENTATION 35
5.2.1 BY APPLICATION 35
5.2.2 BY TECHNOLOGY 35
5.2.3 BY END USER 36
5.3 MARKET DYNAMICS 37
5.3.1 DRIVERS 38
5.3.1.1 Increased R&D expenditure and growth of the biotechnology and pharmaceutical industries 38
5.3.1.2 Increased funding for genomics research 38
5.3.1.3 Technological advancements 39
5.3.1.4 Increasing demand for synthetic genes 39
5.3.1.5 Global rise in production of genetically modified crops 39
?
5.3.2 RESTRAINTS 41
5.3.2.1 Stringent regulatory frameworks and time-consuming approval processes 41
5.3.2.2 Adverse public perception related to genetic research 41
5.3.3 OPPORTUNITY 42
5.3.3.1 Developing countries 42
5.3.4 CHALLENGE 43
5.3.4.1 Off-target effect of CRISPR 43
6 INDUSTRY INSIGHTS 44
6.1 INTRODUCTION 44
6.2 PORTER’S FIVE FORCES ANALYSIS 44
6.2.1 THREAT OF NEW ENTRANTS 44
6.2.2 THREAT OF SUBSTITUTES 45
6.2.3 BARGAINING POWER OF BUYERS 45
6.2.4 BARGAINING POWER OF SUPPLIERS 45
6.2.5 INTENSITY OF RIVALRY 45
6.3 STRATEGIC BENCHMARKING 46
6.4 SUPPLY CHAIN ANALYSIS 46
6.4.1 KEY INFLUENCERS 47
7 GENOME EDITING MARKET, BY APPLICATION 48
7.1 INTRODUCTION 49
7.2 CELL LINE ENGINEERING 50
7.3 ANIMAL GENETIC ENGINEERING 52
7.4 PLANT GENETIC ENGINEERING 54
7.5 OTHER APPLICATIONS 57
8 GENOME EDITING MARKET, BY TECHNOLOGY 60
8.1 INTRODUCTION 61
8.2 CRISPR 62
8.3 TALEN 64
8.4 ZFN 66
8.5 ANTISENSE TECHNOLOGY 68
8.6 OTHER TECHNOLOGIES 70
9 GENOME EDITING MARKET, BY END USER 73
9.1 INTRODUCTION 74
9.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 75
9.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 78
9.4 CONTRACT RESEARCH ORGANIZATIONS 80
?
10 GEOGRAPHIC ANALYSIS 83
10.1 INTRODUCTION 84
10.2 NORTH AMERICA 85
10.2.1 U.S. 90
10.2.2 CANADA 93
10.3 EUROPE 96
10.4 ASIA 100
10.4.1 JAPAN 105
10.4.2 CHINA 108
10.4.3 INDIA 111
10.4.4 REST OF ASIA (ROA) 114
10.5 REST OF THE WORLD (ROW) 117
11 COMPETITIVE LANDSCAPE 121
11.1 OVERVIEW 121
11.2 LEADING PLAYERS IN THE GENOME EDITING MARKET 122
11.3 COMPETITIVE SITUATION AND TRENDS 123
11.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 124
11.3.2 NEW PRODUCT AND SERVICE LAUNCHES 125
11.3.3 ACQUISITIONS 126
11.3.4 EXPANSIONS 127
11.3.5 OTHER DEVELOPMENTS 128
12 COMPANY PROFILES 129
12.1 INTRODUCTION 129
12.2 THERMO FISHER SCIENTIFIC, INC. 130
12.2.1 BUSINESS OVERVIEW 130
12.2.2 PRODUCT PORTFOLIO 130
12.2.3 RECENT DEVELOPMENTS 131
12.2.4 MNM VIEW 132
12.2.4.1 Financial analysis 132
12.2.4.2 Strategic analysis 132
12.3 HORIZON DISCOVERY GROUP PLC 133
12.3.1 BUSINESS OVERVIEW 133
12.3.2 PRODUCT PORTFOLIO 133
12.3.3 RECENT DEVELOPMENTS 133
12.3.4 MNM VIEW 135
12.3.4.1 Strategic analysis 135
?
12.4 SIGMA-ALDRICH CORPORATION 136
12.4.1 BUSINESS OVERVIEW 136
12.4.2 PRODUCT PORTFOLIO 136
12.4.3 RECENT DEVELOPMENTS 137
12.4.4 MNM VIEW 138
12.4.4.1 Financial analysis 138
12.4.4.2 Strategic analysis 138
12.5 GENSCRIPT USA INC. 139
12.5.1 BUSINESS OVERVIEW 139
12.5.2 PRODUCT PORTFOLIO 139
12.5.3 RECENT DEVELOPMENTS 139
12.5.4 MNM VIEW 139
12.5.4.1 Strategic analysis 139
12.6 SANGAMO BIOSCIENCES, INC. 140
12.6.1 BUSINESS OVERVIEW 140
12.6.2 PRODUCT PORTFOLIO 140
12.6.3 RECENT DEVELOPMENTS 141
12.6.4 MNM VIEW 141
12.6.4.1 Strategic analysis 141
12.7 INTEGRATED DNA TECHNOLOGIES, INC. 142
12.7.1 BUSINESS OVERVIEW 142
12.7.2 PRODUCT PORTFOLIO 142
12.7.3 RECENT DEVELOPMENTS 142
12.7.4 KEY STRATEGY 142
12.8 LONZA GROUP LTD. (SWITZERLAND) 143
12.8.1 BUSINESS OVERVIEW 143
12.8.2 PRODUCT PORTFOLIO 143
12.9 NEW ENGLAND BIOLABS, INC. (U.S.) 144
12.9.1 BUSINESS OVERVIEW 144
12.9.2 PRODUCT PORTFOLIO 144
12.10 ORIGENE TECHNOLOGIES, INC. (U.S.) 145
12.10.1 BUSINESS OVERVIEW 145
12.10.2 PRODUCT PORTFOLIO 145
12.10.3 RECENT DEVELOPMENTS 145
12.10.4 KEY STRATEGY 146
12.11 TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (U.S.). 147
12.11.1 BUSINESS OVERVIEW 147
12.11.2 PRODUCT PORTFOLIO 147
12.11.3 RECENT DEVELOPMENTS 148
12.11.4 KEY STRATEGY 148
?
13 APPENDIX 149
13.1 INSIGHTS OF INDUSTRY EXPERTS 149
13.2 DISCUSSION GUIDE 150
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 152
13.4 AVAILABLE CUSTOMIZATIONS 153
13.5 RELATED REPORTS 154
回上頁